Toxic Epidermal Necrolysis Clinical Trial
Official title:
Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.
This is a pilot (preliminary) study. Patients with a diagnosis of TEN will be asked to consider participating. The study intervention is a single intravenous dose of remicaide (5 mg/kg). Standard supportive care will be given. The percentage of patients alive at 30 days after treatment with remicaide will be compared to historical controls. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04711200 -
LYell SYndrome MEsenchymal Stromal Cells Treatment
|
Phase 1/Phase 2 | |
| Completed |
NCT01696500 -
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
|
Phase 3 | |
| Terminated |
NCT02037347 -
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02795143 -
Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study
|
N/A | |
| Withdrawn |
NCT02319616 -
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06119490 -
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
|
Early Phase 1 | |
| Recruiting |
NCT02574988 -
Severe Cutaneous Adverse Reactions in Thailand
|
||
| Not yet recruiting |
NCT03585946 -
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
|